How does WIPO Standard ST.26 relate to the definition of “Modified Nucleotide” in MPEP 2412.03(e)?

MPEP 2412.03(e) directly references WIPO Standard ST.26 for the definition of “Modified Nucleotide”:

“Modified nucleotide” includes any nucleotide as described in paragraph 3(f) of WIPO Standard ST.26.

The MPEP further elaborates on WIPO Standard ST.26’s definition:

“WIPO Standard ST.26, paragraph 3(f), identifies that a “modified nucleotide” means any “nucleotide” as explained in MPEP § 2412.03(d) other than deoxyadenosine 3′-monophosphate, deoxyguanosine 3′-monophosphate, deoxycytidine 3′-monophosphate, deoxythymidine 3′-monophosphate, adenosine 3′-monophosphate, guanosine 3′-monophosphate, cytidine 3′-monophosphate, or uridine 3′-monophosphate.”

This means that WIPO Standard ST.26 provides the foundational definition for “Modified Nucleotide” in patent applications, which is then incorporated into the MPEP guidelines.

To learn more:

• WIPO Standard ST.26
• Modified Nucleotide
• Patent Application
• Biotechnology
• Nucleotide Definition